March 6, 2017 – The U.S. Food and Drug Administration (FDA) has granted pre-market approval (PMA) for the Tryton Side Branch Stent for the treatment of coronary bifurcation lesions involving large side branches. It is the first dedicated bifurcation device to receive regulatory approval in the United States and addresses an unmet need in coronary interventions.

Watch a VIDEO demonstration of the deployment for the Tryton Dedicated Bifurcation Stent.

Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new BioFreedom Pivotal Study. The study will be conducted under an Investigational Device Exemption (IDE), which will include sites in the United States, Canada, Denmark, France Germany and Italy.

Dee Dee Wang, Henry Ford Hospital, 3D printing for cardiology, 3-D

March 3, 2017 — A Henry Ford Hospital study found a 100 percent success rate in left atrial appendage (LAA) occlusion procedures when 3-D imaging was used instead of traditional 2-D imaging, the Journal of American College of Cardiology has reported.

March 3, 2017 — In a United Kingdom patent case involving a Edwards Lifesciences lawsuit against Boston Scientific for what the company said are invalid patents related to transcatheter valve seals, the court today ruled one of Boston's patents invalid, while a second patent is valid. Edwards said in a statement it will promptly request an appeal on specific aspects of the decision. 

The patent case is over the outer seals for Boston’s transcatheter Lotus heart valve and Edwards’ Sapien 3 valve. The seals are used to prevent paravalvular leak. 

Complex PCI Masters’ Forum

Philips recently announced the global launch of Azurion, its next-generation image-guided therapy platform.

In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers demonstrate that a new positron emission tomography (PET) radiotracer, gallium-68 (Ga-68)-pentixafor, can quickly and non-invasively identify life-threatening atherosclerotic plaques. The tracer binds to the CXCR4 receptor on inflammatory cells present in atherosclerotic plaques — making it possible to find and treat atherosclerosis early.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now